BioHarvest sets Q4 and 2025 results date

BioHarvest Sciences Inc. filed a Form 6-K to share that it will release its fourth quarter and full year 2025 financial results after market close on March 31, 2026.

Rhea-AI Filing Summary

BioHarvest Sciences Inc. filed a Form 6-K to share that it will release its fourth quarter and full year 2025 financial results after market close on March 31, 2026. On the same day, the company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time to discuss the results and provide a business update.

The webcast will be accessible through an online registration link, with a replay later available in the Investor Relations Events & Presentations section of the company’s website. The filing also reiterates BioHarvest’s focus on its proprietary Botanical Synthesis platform and notes standard forward-looking statement cautions.

FAQ

When will BioHarvest Sciences (BHST) report Q4 and full year 2025 results?

BioHarvest Sciences plans to report its fourth quarter and full year 2025 financial results after market close on March 31, 2026. The company will also host a conference call and webcast that afternoon to discuss the results and provide a business update.

What time is BioHarvest Sciences’ Q4 and 2025 earnings call on March 31, 2026?

The BioHarvest Sciences earnings call is scheduled for 4:30 p.m. Eastern Daylight Time on March 31, 2026. A live webcast will accompany the call, and a replay will later be posted in the Investor Relations Events & Presentations section of the company’s website.

How can investors access the BioHarvest Sciences (BHST) March 31, 2026 earnings webcast?

Investors can access the BioHarvest Sciences webcast through an online event link provided by the company. Attendees are encouraged to register at least 10 minutes before the 4:30 p.m. Eastern Daylight Time start to ensure timely participation, with a replay later available on the company’s website.

What business does BioHarvest Sciences (BHST) focus on according to this filing?

BioHarvest Sciences focuses on its proprietary Botanical Synthesis technology platform to grow plant-based compounds without cultivating the whole plant. It operates as a CDMO for novel plant-based compounds and develops proprietary nutraceutical health and wellness products, including dietary supplements, based on its technology.

Where can investors find BioHarvest Sciences (BHST) SEC risk factor disclosures?

Investors can find BioHarvest Sciences’ risk factor disclosures within its filings available in the Investor Relations section of the company’s website and on the SEC’s website at www.sec.gov. These sections summarize key risks referenced in the forward-looking statements language in this communication.

Who is the corporate contact for BioHarvest Sciences mentioned in the 6-K?

The corporate contact listed is Dave Ryan, reachable at telephone number (604) 622-1186 and via email at info@bioharvest.com. An additional investor relations contact is Chuck Padala of LifeSci Advisors, who can be contacted at chuck@lifesciadvisors.com for investor-related inquiries.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 03:40 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission file number: 001-42389

BIOHARVEST SCIENCES INC.

(Exact name of Registrant as specified in its charter)

Not applicable

(Translation of Registrant’s name into English)

1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☐ Form 20-F ☒ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SUBMITTED HEREWITH

Exhibits:

Exhibit	Description
99.1	News Release dated March 17, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOHARVEST SCIENCES INC.
	(Registrant)
Date: March 17, 2026	/s/ David Ryan
	Name: David Ryan
	Title: Vice-President, Investor Relations & Secretary

BioHarvest Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026

Vancouver, British Columbia and Rehovot, Israel – March 17, 2026 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”), (NASDAQ: BHST) (FSE: 8MV0), a company pioneering its proprietary Botanical Synthesis™ platform, today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 31, 2026. The Company will host a conference call and webcast at 4:30 p.m. Eastern Daylight Time to discuss the results and provide an update on business operations.

Fourth Quarter and Full Year 2025 Earnings Call

Date:Tuesday, March 31, 2026 

Time:4:30 PM Eastern Time 

Webcast link:https://events.q4inc.com/attendee/512060117 

The Earnings call webcast will be broadcast live, and attendees are encouraged to register via the webcast link at least 10 minutes prior to the call to ensure timely participation.

The webcast recording will be available for replay on the Company’s website within the Investor Relations/Events & Presentations section.

About BioHarvest Sciences Inc.

BioHarvest (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures. Forward-looking statements include those set forth in the Risk Factors section of the Company’s Securities and Exchange Commission (SEC)’s filings which can be found within the Investor Relations section on the Company’s website, or on the SEC’s website at http://www.sec.gov.

BioHarvest Corporate Contact:

Dave Ryan

(604) 622-1186

info@bioharvest.com

Investor Relations Contact:

Chuck Padala, Managing Director

LifeSci Advisors

chuck@lifesciadvisors.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 NEWS RELEASE DATED MARCH 17, 2026 9.1 KB